The Trailhead evaluation data highlights improvements in key physical markers, specifically reduced fat infiltration, better upper-limb performance, and increased handgrip strength. Perry Shieh, a professor at the UCLA David Geffen School of Medicine, noted that the consistency across safety and strength metrics offers a promising outlook for the candidate’s future clinical path.

Chief Executive Frank Gleeson confirmed these findings bolster the ongoing Basecamp study, a phase 2 trial for the same drug. The company expects to finalize patient enrollment for that study by the end of the third quarter.